581 Preliminary phase 1 results of clinical trial investigating BI-1910, a tumor necrosis factor receptor 2 (TNFR2) agonist, in solid tumor cancer patients

581 Figure 1 Induction of proliferating (Ki-67+) memory CD4+ T cells was observed after BI-1910 monotherapy at doses >100 mg.Sustained T cell proliferation was associated with disease control